The L-valyl ester prodrug of acyclovir, providing 3-5 times higher oral bioavailability than acyclovir. This allows less frequent dosing (2-3 times daily vs 5 times daily) with equivalent or superior efficacy. Used for genital herpes (initial, recurrent, and suppressive therapy), herpes zoster (shingles), herpes labialis (cold sores), and reduction of HSV transmission to uninfected partners. The preferred oral agent for herpes infections in most clinical scenarios.
Reduces transmission of genital HSV-2 to uninfected partners by ~50%6
Convenient dosing (2-3 times daily vs 5 times daily for acyclovir)8,10
What to watch for
Headache
Nausea
Abdominal pain
Known hypersensitivity to valacyclovir, acyclovir, or any component10,1
Severe renal impairment without dose adjustment3,4
The bottom line
Evidence rating strong. Most-documented uses: treats and suppresses genital herpes (preferred oral agent), treats herpes zoster (shingles), better bioavailability than acyclovir, treats herpes labialis (cold sores), 1-day treatment. 10 sources indexed (2023–2026), with 2 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Rapidly converted to acyclovir and L-valine by first-pass intestinal and hepatic esterases (valacyclovir hydrolase). Acyclovir is then selectively phosphorylated by viral thymidine kinase in HSV/VZV-infected cells and subsequently by cellular kinases to acyclovir triphosphate. The active triphosphate competitively inhibits viral DNA polymerase and serves as a DNA chain terminator upon incorporation into viral DNA, halting replication.1,8
Class
Nucleoside Analog Antiviral (Prodrug)
Dosing
Dosing & protocol.
Common range
Genital herpes initial: 1 g BID x 10 days; recurrent: 500 mg BID x 3 days; suppressive: 500 mg-1 g daily; herpes zoster: 1 g TID x 7 days; cold sores: 2 g BID x 1 day (as prescribed by your physician)
Recommended form
Oral tablets (caplets)
Oral bioavailability of acyclovir from valacyclovir is approximately 54% (vs 15-30% for oral acyclovir). Food does not significantly affect absorption. Rapidly and nearly completely converted to acyclovir after absorption. Maintain adequate hydration.3,4
Safety
Full safety detail.
Side effects
Headache
Nausea
Abdominal pain
Dizziness
Renal impairment (rare, especially with high doses in immunocompromised)
Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS, rare, in immunocompromised at high doses)
Contraindications
Known hypersensitivity to valacyclovir, acyclovir, or any component10,1
Severe renal impairment without dose adjustment3,4
TTP/HUS history (especially in immunocompromised patients at high doses)
Advanced HIV disease or post-transplant patients at doses >8 g/day (TTP/HUS risk)4,2
Valacyclovir is the prodrug of acyclovir, and L-lysine prophylaxis works through a separate, arginine-competition mechanism against HSV. Evidence is modest and best supported for daily doses above 1 g, but there is no known pharmacokinetic interaction with valacyclovir, and combination use is reasonable for recurrence prevention.
Recommendation: Lysine 1-3 g/day is a reasonable adjunct to valacyclovir for recurrent HSV. Continue valacyclovir as prescribed during active outbreaks; do not rely on lysine alone.
Vitamin C has in vitro antiviral effects against HSV and supports immune function; combined with valacyclovir for recurrent HSV it offers a mechanism-distinct adjunct without known pharmacokinetic interference. Evidence for additive clinical benefit is preliminary but the combination is low risk at standard supplement doses.
Recommendation: Vitamin C 500-1000 mg/day is reasonable as adjunctive immune support during HSV outbreaks while on valacyclovir. Do not stop prescribed antivirals in favor of vitamin C.
Chatzakis C, Shahar-Nissan K, Faure-Bardon V et al.. The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis. American journal of obstetrics and gynecology. 2024
Cohen EJ, Troxel AB, Liu M et al.. Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial. JAMA ophthalmology. 2025
Warner DB, Jeng BH, Kim J et al.. Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study: A Randomized Clinical Trial. JAMA ophthalmology. 2025
Linden DA, Guo-Parke H, McKelvey MC et al.. Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD: A Randomized Double-Blind Placebo-Controlled Trial. Chest. 2023
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Valacyclovir in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack